One molecular target of particular relevance to lung cancer pathogenesis is the EGF receptor (EGFR). The EGFR (also known as ErbB-1/HER1) is a 170-kDa transmembrane glycoprotein that consists of ...
Discover Lyell Immunopharma's groundbreaking patent for EGFR-derived polypeptides, enhancing cancer treatment through innovative nucleic acid technologies and engineered T cells.
The EGF receptor (EGFR) was the first receptor to be proposed for cancer therapy and two EGFR-targeted pharmacologic approaches have been successfully developed: monoclonal antibodies (mAbs ...
There is strong evidence that epidermal growth factor receptor (EGFR) plays a role in tumor progression. A new study by Spano et al. has examined the relationship between EGFR expression ...
The FDA has approved Rybrevant in combination with carboplatin and pemetrexed for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer ...
Knock-outs for cancer The epidermal growth factor receptor (EGFR) is a well-studied protein: dysregulation in the EGFR pathway is implicated in various cancers. In order to test whether antibodies ...